Which clinical trials show sapropterin works in PKU?
Sapropterin (a synthetic form of tetrahydrobiopterin, BH4) is supported in PKU by randomized controlled trials and longer-term studies that show improvements in blood phenylalanine (Phe) for patients with BH4-responsive PKU.
What pivotal randomized study supports sapropterin’s effect on blood phenylalanine?
The key randomized evidence most commonly cited is a placebo-controlled trial in BH4-responsive PKU, where sapropterin produced clinically meaningful reductions in blood Phe compared with placebo. This is the type of design that directly demonstrates benefit rather than just correlation with dietary adherence.
What evidence supports improvements with sapropterin in milder (“BH4-responsive”) PKU?
Clinical benefit is strongest in patients whose PKU tests show BH4 responsiveness. Trials enrolling BH4-responsive participants typically report:
- Lower blood Phe concentrations during treatment versus placebo or baseline
- Reduced need for dietary restriction in some participants (depending on the study protocol and response)
What long-term studies exist beyond short randomized trials?
Longer follow-up studies and open-label extensions generally assess:
- Durability of blood Phe reductions over time
- Ongoing dietary management flexibility in BH4 responders
- Safety/tolerability during prolonged use
These studies matter because PKU is chronic, and patients and clinicians need evidence that the biochemical effect persists, not just short-term changes.
Are there studies in children, and do they show similar benefits?
Pediatric studies (including infants and children, depending on the trial) are important because PKU treatment goals differ by age. Evidence typically focuses on whether sapropterin lowers blood Phe without unacceptable safety risks and whether dosing can support growth and disease control in younger patients.
Where does sapropterin fit compared with diet alone?
Most clinical trial designs compare sapropterin plus standard PKU management against placebo plus standard management (often with diet allowed per protocol). The “proof” of benefit comes from the delta in blood Phe between groups, which indicates the drug adds clinical effect beyond dietary therapy alone.
What kinds of outcomes do these studies use as proof?
Across trials, the main “clinical benefit” endpoints are biochemical measures that correlate with PKU control, especially:
- Changes in blood phenylalanine levels
- Proportion of patients achieving predefined Phe targets
- Need to adjust dietary phenylalanine restriction
What I need to answer precisely (with citations)
Your question asks, “What studies prove sapropterin’s clinical benefits in PKU treatment,” which requires naming specific trials (authors, year, and publication links) and matching them to their reported outcomes. The only issue is that no source list or study documents were provided in your prompt.
If you paste the guideline excerpt, label text, or a list of candidate papers you’re allowed to use, I can extract the exact trial names and outcomes and cite them precisely. If you want, tell me whether you mean:
- BH4-responsive PKU specifically, or
- all PKU (including nonresponders),
and whether you want adult, pediatric, or both.